Biosimilars Market 2025: The Critical Role of Rising Prevalence Of Chronic Diseases Sparks Growth In The Biosimilars Market Driver in Industry Evolution

 

biosimilars market outlook, biosimilars market size, biosimilars market share, biosimilars market growth, biosimilars market overview, biosimilars market research

What are the recent trends in market size and growth for the biosimilars market?
The biosimilars market size has grown rapidly in recent years. It will grow from $18.65 billion in 2024 to $21.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%.  The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, a strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $42.16 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%.  The growth in the forecast period can be attributed to the increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Major trends in the forecast period include a focus on robust R&D activities for the development of effective and innovative drugs, on focus on M&A growth strategies, a focus on establishing strategic partnerships, a focus on increasing investments, and a focus on artificial intelligence.

Get Your Free Sample of The Global Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

How have varous drivers impacted the growth of the biosimilars market?
The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.

What are the primary segments of the biosimilars market?
The biosimilars market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others
2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:
1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars
2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars
3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars
4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars
6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which firms are leading the biosimilars market?
Major companies operating in the biosimilars market include  Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

How will industry trends affect the trajectory of the biosimilars market?
Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge in the market. AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases. For instance, in January 2023, Amgen Inc., a US-based biotechnology company, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now available in the US. AMJEVITA (40 mg) is available at a list price (wholesale acquisition cost) 55% below the current Humira list price. AMJEVITA is also available at a list price 5% below the current Humira list price.

Which geographic trends are shaping the biosimilars market, and which region has the highest market share?
The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

What Does The Biosimilars Market Report 2025 Offer?
The biosimilars market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model